| Autor: |
Altomonte J; II. Medizinische Klinik, Klinikum rechts der Isar der TU München; Jennifer.Altomonte@lrz.tu-muenchen.de., Muñoz-Álvarez KA; Department of Nuclear Medicine, Klinikum rechts der Isar der TU München., Shinozaki K; Division of Clinical Oncology, Hiroshima Prefectural Hospital., Baumgartner C; Center for Preclinical Research, Klinikum rechts der Isar der TU München., Kaissis G; Institute for Diagnostic and Interventional Radiology, Klinikum rechts der Isar der TU München., Braren R; Institute for Diagnostic and Interventional Radiology, Klinikum rechts der Isar der TU München., Ebert O; II. Medizinische Klinik, Klinikum rechts der Isar der TU München. |
| Abstrakt: |
Hepatocellular carcinoma (HCC) is a disease with limited treatment options and poor prognosis. In recent years, oncolytic virotherapies have proven themselves to be potentially powerful tools to fight malignancy. Due to the unique dual blood supply in the liver, it is possible to apply therapies locally to orthotopic liver tumors, which are predominantly fed by arterial blood flow. We have previously demonstrated that hepatic arterial delivery of oncolytic viruses results in safe and efficient transduction efficiency of multifocal HCC lesions, resulting in significant prolongation of survival in immune competent rats. This procedure closely mimics the application of transarterial embolization in patients, which is the standard palliative care provided to many HCC patients. The ability to administer tumor therapies through the hepatic artery in rats allows for a highly sophisticated preclinical model for evaluating novel viral vectors under development. Here we describe the detailed protocol for microdissection of the hepatic artery for infusion of oncolytic virus vectors to treat orthotopic HCC. |
